NASDAQ:BLPH
Bellerophon Therapeutics Stock News
$0.0625
+0.0112 (+21.83%)
At Close: May 02, 2024
Bellerophon to Present at the H.C. Wainwright 6th Annual Israel Conference
08:30am, Wednesday, 11'th Nov 2020
WARREN, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2020 Financial Results
08:30am, Thursday, 05'th Nov 2020
WARREN, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t
WARREN, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t
Bellerophon Appoints Cardiopulmonary Disease Expert Wassim Fares, M.D., MSCR, as Chief Medical Officer
12:30pm, Tuesday, 11'th Aug 2020
WARREN, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2020 Financial Results
12:30pm, Wednesday, 05'th Aug 2020
WARREN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing t
DAVENPORT & Co LLC Invests $1.35 Million in Bellerophon Therapeutics Inc (NASDAQ:BLPH)
10:52am, Saturday, 01'st Aug 2020
DAVENPORT & Co LLC purchased a new position in Bellerophon Therapeutics Inc (NASDAQ:BLPH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission
Galera Phase 2 Trial, And Other News: The Good, Bad And Ugly Of Biopharma
05:43pm, Wednesday, 15'th Jul 2020
Galera completed enrollment for its Phase 1b/2a clinical trial of avasopasem manganese or GC4419. Albireo enrolled the first patient in its Phase 3 clinical trial of Odevixibat.
Patients Treated with INOpulse® Demonstrated Improved Physical Activity Compared to Placebo Live Webinar with Study Investigators on Thursday, July 16th, from 4:00-5:00 pm EDT.
WARREN, N.J., July 13, 2020 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and.
Bellerophon Therapeutics Added to Russell 3000® and Microcap® Indexes
12:00pm, Monday, 29'th Jun 2020
Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious lung diseases, today announced that the company has
Is Bellerophon Therapeutics, Inc. (BLPH) A Good Stock To Buy?
10:42pm, Thursday, 04'th Jun 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Alan Fournier Adds 4 Stocks to Portfolio
07:40pm, Friday, 29'th May 2020
Guru releases 1st-quarter portfolio Continue reading...
Bellerophon intends to use the net proceeds from the Offerings, together with its current cash and cash equivalents, for funding its ongoing clinical trials, working capital needs and other general co
8 Biotechs Tapping Secondary Markets for $3 Billion
10:53pm, Tuesday, 19'th May 2020
Company stocks drop on dilution, but monies could benefit shareholders down the line Continue reading...
Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering
11:00am, Tuesday, 19'th May 2020
WARREN, N.J., May 19, 2020 -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the pricing of offerings for an aggregate of.
